Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154815 | 0.88 | RAB9A (0.46) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL11928813 | 0.88 | RAB9A (0.39) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL3350172 | 0.86 | MAPK1 (0.41) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL854822 | 0.86 | S1PR1 (0.42) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL5287165 | 0.86 | NOTUM (0.41) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL20427474 | 0.84 | RAB9A (0.49) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL19364783 | 0.84 | RAB9A (0.42) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL21350422 | 0.83 | S1PR1 (0.40) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL5283890 | 0.81 | MAPK1 (0.36) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL5297276 | 0.80 | VHL (0.42) | S1PR1S1PR3ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200190019-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-18 | — | — | US | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | S1PR1 809/4885S1PR3 820/4885ALDH1A1 1664/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | S1PR1 3018/4885S1PR3 2747/4885ALDH1A1 201/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | S1PR1 1117/4885S1PR3 1165/4885ALDH1A1 365/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | S1PR1 3018/4885S1PR3 2747/4885ALDH1A1 201/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | S1PR1 3511/4885S1PR3 3210/4885ALDH1A1 287/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | S1PR1 2523/4885S1PR3 2406/4885ALDH1A1 132/4885 |
| US-20200190019-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | S1PR1 809/4885S1PR3 820/4885ALDH1A1 1664/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | S1PR1 1579/4885S1PR3 1474/4885ALDH1A1 1520/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | S1PR1 1579/4885S1PR3 1474/4885ALDH1A1 1520/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | S1PR1 809/4885S1PR3 820/4885ALDH1A1 1664/4885 |
| US-10035819-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | S1PR1 1579/4885S1PR3 1474/4885ALDH1A1 1520/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | S1PR1 2523/4885S1PR3 2406/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.